Gastroesophageal Cancer – Landscape & Forecast – Disease Landscape & Forecast (G7)

Immune checkpoint inhibitors Opdivo (Bristol Myers Squibb / Ono Pharmaceutical) and Keytruda (Merck & Co.) have revolutionized the treatment of gastroesophageal cancer, driving substantial market growth. Multimodal therapy, including HER2-targeted agents, immune checkpoint inhibitors, and chemotherapy, is now the standard for HER2- and PD-L1-positive disease. The recent approval of the first-in-class claudin-18.2 inhibitor Vyloy (Astellas), along with the anticipated approval of novel biomarker-driven approaches such as the FGFR2b-inhibitor bemarituzumab is expected to reshape market dynamics in the HER2-negative setting. Given the significant progress in the late-phase pipeline, we anticipate the approval of several new therapies, including Ziihera (Jazz Pharmaceuticals) and Imfinzi (AstraZeneca), for gastroesophageal cancer during the forecast period.

Questions answered

• How is gastroesophageal cancer segmented by subpopulation, and what is the size of the drug-treatable and drug-treated populations?
• What are the key current therapies for gastroesophageal cancer, and how are they positioned in the treatment algorithm?
• Which emerging therapies are the most promising, and how will they shape the future of the gastroesophageal cancer therapy market?
• What are the drivers of and constraints on the gastroesophageal cancer therapy market, and how will the market evolve over the forecast period?

Content highlights

Geography: United States, EU5, Japan

Primary research: 19 country-specific interviews with thought-leading medical oncologists, supported by survey data collected for this and other Clarivate research.

Epidemiology: Diagnosed and recurrent incidence of gastroesophageal cancer by country, segmented by stage of disease, histology, HER2 status, and line of therapy

Forecast: 10-year, annualized, drug-level sales and patient share of key gastroesophageal cancer therapies through 2034, segmented by brands / generics / biosimilars and drug-treatable populations

Drug treatments: Coverage of key current and emerging therapies

Product description

Disease Landscape & Forecast offers comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:

• Optimize your long-term disease and development strategy.
• Quantify market potential for your pipeline assets and those of your competitors.
• Understand a disease from top to bottom, including key patient populations, the current and future therapeutic landscape, and the evolving market trajectory.
• Gauge the commercial outlook and impact of key market events.